170 related articles for article (PubMed ID: 37426835)
1. Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.
Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F
Ther Adv Hematol; 2023; 14():20406207221147777. PubMed ID: 37426835
[TBL] [Abstract][Full Text] [Related]
2. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
Hughes DM; Toste C; Nelson C; Escalon J; Blevins F; Shah B
J Adv Pract Oncol; 2021 Jul; 12(5):508-517. PubMed ID: 34430061
[TBL] [Abstract][Full Text] [Related]
3. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Carpenedo M; Baldacci E; Baratè C; Borchiellini A; Buccisano F; Calvaruso G; Chiurazzi F; Fattizzo B; Giuffrida G; Rossi E; Palandri F; Scalzulli PR; Siragusa SM; Vitucci A; Zaja F
Ther Adv Hematol; 2021; 12():20406207211048361. PubMed ID: 34646432
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K; Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
[TBL] [Abstract][Full Text] [Related]
6. Immune thrombocytopenia.
Bussel J; Cooper N; Boccia R; Zaja F; Newland A
Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
Ann Hematol; 2024 Jun; ():. PubMed ID: 38856778
[TBL] [Abstract][Full Text] [Related]
8. Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib.
Innao V; Calogero RD; Lo Presti F; Consoli U
Case Rep Hematol; 2023; 2023():9953245. PubMed ID: 37323813
[TBL] [Abstract][Full Text] [Related]
9. Sustained response off therapy after fostamatinib: A chronic refractory ITP case report.
Auteri G; Biondo M; Mazzoni C; Venturi M; Romagnoli AD; Paglia S; Cavo M; Vianelli N; Palandri F
Heliyon; 2023 Feb; 9(2):e13462. PubMed ID: 36846652
[TBL] [Abstract][Full Text] [Related]
10. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB
Ther Adv Hematol; 2021; 12():20406207211010875. PubMed ID: 33995988
[TBL] [Abstract][Full Text] [Related]
11. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
12. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
13. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series.
Liu J; Hsia CC
Adv Hematol; 2022; 2022():8119270. PubMed ID: 36393999
[TBL] [Abstract][Full Text] [Related]
16. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
17. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management.
Provan D; Thachil J; Álvarez Román MT
Expert Rev Hematol; 2024; 17(1-3):55-66. PubMed ID: 38369947
[TBL] [Abstract][Full Text] [Related]
18. Current approaches for the diagnosis and management of immune thrombocytopenia.
Gafter-Gvili A
Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
[TBL] [Abstract][Full Text] [Related]
19. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
